Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Berichten met het trefwoord ‘lung cancer’

Lung cancer doctors eye Merck’s Keytruda over Bristol’s Opdivo

Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.

Bron: Reuters Meer lezen »

Nice backs two cancer drugs from Novartis

The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer and skin cancer.The recommendation is part of the final approvals for five drugs to treat four different conditions to be funded by the NHS. The regulator has backed Novartis’ Zykadia (ceritinib) to treat non-small-cell lung cancer […]

Bron: Meer lezen »

Synta halts study of lung cancer treatment, stock plummets

Synta Pharmaceuticals Corp has decided to end a late-stage trial of its lung cancer treatment after an independent review said it proved ineffective, nearly halving its stock in extended trading on Tuesday.

Bron: Reuters Meer lezen »

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug in its second indication. BMS adds lung cancer to advanced melanoma in the list of conditions for which the drug is available, after its launch as a treatment for locally advanced or metastatic squamous non-small cell […]

Bron: Meer lezen »

Roche lung cancer treatments perform

Roche has revealed promising trial data from two lung cancer treatments with one improving survival and the other shrinking tumours. Its experimental immunotherapy MPDL3280A has been shown to double the likelihood of survival compared with chemotherapy in people with a specific type of lung cancer.    

Bron: Meer lezen »

Merck Serono finally ditches lung cancer vaccine

Merck Serono says it will scrap trials of its investigational lung cancer drug after years of struggling to make it work. The pharmaceuticals unit of Merck KGaA says it will no longer study the investigational MUC1 antigen-specific cancer immunotherapy tecemotide in non-small cell lung cancer (NSCLC) patients.  

Bron: Meer lezen »

Lung cancer vaccine dropped

GlaxoSmithKline took a hit today after its lung cancer vaccine MAGE-A3 failed to benefit patients. The London-based firm has now stopped the Phase III MAGRIT trial, which was assessing the MAGE-A3 cancer immunotherapeutic in non-small cell lung cancer (NSCLC) patients. It took this decision after establishing that it will not be possible to identify a […]

Bron: Meer lezen »